| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Mclean Hospital |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000210 |
Purpose
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.
| Condition | Intervention | Phase |
|
Cocaine-Related Disorders Heroin Dependence |
Drug: Buprenorphine |
Phase II |
| MedlinePlus related topics: | Heroin |
| Drug Information available for: | Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Treatment Efficacy for Drug Abuse and AIDS Prevention |
Eligibility
| Ages Eligible for Study: | 26 Years to 41 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Massachusetts | |||||
| McLean Hospital, Dept. of Psychiatry | |||||
| Belmont, Massachusetts, United States, 2178 | |||||
| National Institute on Drug Abuse (NIDA) |
| Mclean Hospital |
| Principal Investigator: | Jack Mendelson, M.D. | Mclean Hospital |
More Information
| Study ID Numbers: | NIDA-06116-1, R18-06116-1 |
| First Received: | September 20, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000210 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
